Trial reportScientific reports2025
The efficiency and safety of low-dose intravenous indomethacin for closure of patent ductus arteriosus in preterm neonate: a randomized controlled trial.
Trial report in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Patent ductus arteriosus (PDA) is a common complication in prematurity. Intravenous indomethacin, three doses, is an effective medication for closure PDA, but complications about renal impairment and gastrointestinal (GI) problems should be considered. This study aimed to compare the efficacy and safety of low-dose intravenous indomethacin (two doses) with the conventional three-dose for the closure of PDA in preterm neonates. A Randomized, Controlled, non-inferiority trial was performed from 1 May 2021 to February 2024. Preterm neonates <34 weeks or body weight <1,500 g with age <6 days with hemodynamically significant PDA were included. The patients were randomized into 2 groups: Group 1, 64 patients received 2 doses of indomethacin (0.2 mg/kg/dose), and Group 2, 64 patients received 3 doses of indomethacin. The baseline characteristics of both groups (gestational age (GA), gender, birth weight, respiratory disease, respiratory support, PDA size, left atrium/aorta ratio, and age of first indomethacin) show no statistically significant differences. The success rate for closure PDA in 72 h and 7 days has no statistically significant difference. The incidence of re-medication and surgical closure PDA, Necrotizing enterocolitis, GI bleeding, acute kidney injury, death, and hospital stay shows no statistically significant differences. Low-dose of Intravenous indomethacin was similar in efficiency and safety for closure of PDA in preterm newborns as the conventional dose, especially in preterm neonates with birth weight ≥ 1000 gm and GA > 28 weeks. This study was approved by the institutional review board of Chonburi hospital (040/2564) and was registered on Thai Clinical Trials Registry (TCTR20241122001) (22/11/2024).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.